Detalhe da pesquisa
1.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Cell
; 170(6): 1120-1133.e17, 2017 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28803728
2.
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
; 606(7915): 797-803, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35705814
3.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
; 613(7945): E3, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627494
4.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Proc Natl Acad Sci U S A
; 116(45): 22699-22709, 2019 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31636208
5.
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 19(2): 181-193, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361468
6.
The good, the (not so) bad and the ugly of immune homeostasis in melanoma.
Immunol Cell Biol
; 96(5): 497-506, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29392770
7.
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
Mol Cancer
; 16(1): 112, 2017 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28659148
8.
Hallmarks of response to immune checkpoint blockade.
Br J Cancer
; 117(1): 1-7, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28524159
9.
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Br J Cancer
; 116(12): 1558-1563, 2017 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28524161
10.
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Australas J Dermatol
; 58(3): e109-e112, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27170423
11.
Systems analysis identifies miR-29b regulation of invasiveness in melanoma.
Mol Cancer
; 15(1): 72, 2016 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27852308
12.
Evolving role of tumor antigens for future melanoma therapies.
Future Oncol
; 10(8): 1457-68, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25052755
13.
Gut microbiota - a double-edged sword in cancer immunotherapy.
Trends Cancer
; 9(1): 3-5, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36088249
14.
Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice.
Aust J Gen Pract
; 52(6): 378-385, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37291817
15.
UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma.
Oncogene
; 42(17): 1360-1373, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906655
16.
Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma.
Clin Transl Immunology
; 12(9): e1466, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37692904
17.
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Br J Cancer
; 116(8): e15, 2017 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28324885
18.
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study.
Cardiooncology
; 8(1): 23, 2022 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36461057
19.
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383113
20.
Multi-modal molecular programs regulate melanoma cell state.
Nat Commun
; 13(1): 4000, 2022 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810190